미국의 일반의약품 포도당 바이오센서 시장 규모, 점유율, 동향 분석 보고서 : 용도별, 주요 기업별, 경쟁 분석, 부문 예측(2025-2030년)

U.S. OTC Glucose Biosensors Market Trends:

The U.S. over-the-counter glucose biosensors market size was estimated at USD 105.3 million in 2024 and is anticipated to exhibit a CAGR of 11.5% from 2025 to 2030. This growth is attributed to the increasing prevalence of diabetes and prediabetes, the shift towards preventive healthcare, and the increased adoption of glucose biosensors by athletes are some of the major factors driving market growth. Moreover, the aging population of the country further contributes to this growth as this age group is significantly vulnerable to chronic diseases such as diabetes, which increases the demand for effective solutions such as glucose biosensors.

The increase in the prevalence of diabetes due to aging, obesity, and unhealthy lifestyle is one of the factors contributing to the growth of the U.S. over-the-counter (OTC) glucose biosensors industry. Obesity is a major factor leading to diabetes. According to CBS News published in September 2024, approximately 30% of adults were classified as obese, with a body mass index (BMI) of 30 or higher in 2020. Furthermore, the CDC reported an increase in the adult obesity rate to 41.9% by 2020. Currently, based on survey data from 2021 to 2023, the CDC estimates that 40.3% of adults are obese. In addition to obesity, diabetes is becoming increasingly prevalent globally. The International Diabetes Federation (IDF) estimates that there were 537 million adults (aged 20-79) living with diabetes in 2021, and this number is expected to increase to 642 million by 2040. The IDF also reports that the prevalence of diabetes is growing globally, with the highest increase witnessed in low- and middle-income countries.

In the U.S., diabetes is a widespread health issue affecting millions of people. According to the CDC, as of 2024, 11.6% of the entire U.S. population-about 38.4 million people of all ages-has been diagnosed with diabetes. The percentage of adults aged 18 or older is even higher, with 14.7% or 38.1 million people affected. Around 8.7 million adults with diabetes were unaware of their condition or did not report it, representing 22.8% of all adults with diabetes and 3.4% of all U.S. adults. The risk of diabetes increases with age, with the percentage of adults with diabetes peaking at 29.2% among those aged 65 or above. These statistics highlight the significant impact that diabetes has on the U.S. population.

Moreover, the shift towards preventive healthcare is also contributing to the growth of the U.S. over-the-counter (OTC) glucose biosensors industry. Consumers increasingly prioritize health management to avoid chronic diseases such as diabetes, driven by rising awareness, government initiatives, and technological advancements. Preventive healthcare emphasizes early detection and continuous monitoring, fueling demand for accessible and user-friendly glucose monitoring devices.

OTC glucose biosensors such as Stelo and Lingo provide individuals with convenient, non-prescription options to monitor blood glucose levels at home. These devices offer ease of use with compact designs and seamless smartphone integration for real-time tracking and data analysis. Stelo and Lingo support proactive health management, enabling users to detect early changes in their glucose levels and take timely action, promoting a preventive approach to diabetes care.

U.S. Over-the-Counter Glucose Biosensors Market Report Segmentation

This report forecasts revenue growth at country levels and analyzes the latest industry trends in each of the sub-segments from 2018 to 2030. For this study, Grand View Research has segmented the U.S. over-the-counter glucose biosensors market report based on end use:

• End-use Outlook (Revenue, USD Million, 2018 - 2030)
• Healthcare Professional Offices (HCPs)
• Specialty Clinics
• Homecare

Table of Contents

Chapter 1. Methodology and Scope

• 1.1. Market Segmentation and Scope
• 1.2. Market Definitions
• 1.3. Research Methodology
  • 1.3.1. Information Procurement
  • 1.3.2. Information or Data Analysis
  • 1.3.3. Market Formulation & Data Visualization
  • 1.3.4. Data Validation & Publishing
• 1.4. Research Scope and Assumptions
  • 1.4.1. List of Data Sources

Chapter 2. Executive Summary

• 2.1. Market Outlook
• 2.2. Segment Outlook
• 2.3. Competitive Insights

Chapter 3. U.S. Over the Counter (OTC) glucose biosensors Market Variables, Trends, & Scope

• 3.1. Market Introduction/Lineage Outlook
• 3.2. Market Size and Growth Prospects (USD Million)
• 3.3. Market Dynamics
  • 3.3.1. Market Drivers Analysis
    • 3.3.1.1. Increasing prevalence of diabetes and prediabetes
    • 3.3.1.2. Shift towards preventive healthcare
    • 3.3.1.3. Increased adoption of glucose biosensors by athletes
  • 3.3.2. Market Restraints Analysis
    • 3.3.2.1. Lack of coverage under insurance plans
    • 3.3.2.2. Limitations in OTC biosensors functionality
    • 3.3.2.3. Regulatory challenges
• 3.4. U.S. Over-the-Counter (OTC) Glucose Biosensors Market Analysis Tools
  • 3.4.1. Porter's Analysis
    • 3.4.1.1. Bargaining power of the suppliers
    • 3.4.1.2. Bargaining power of the buyers
    • 3.4.1.3. Threats of substitution
    • 3.4.1.4. Threats from new entrants
    • 3.4.1.5. Competitive rivalry
  • 3.4.2. PESTEL Analysis
    • 3.4.2.1. Political landscape
    • 3.4.2.2. Economic and Social landscape
    • 3.4.2.3. Technological landscape
    • 3.4.2.4. Environmental landscape
    • 3.4.2.5. Legal landscape

Chapter 4. U.S. Over-the-Counter (OTC) Glucose Biosensors Market: End Use Estimates & Trend Analysis

• 4.1. Segment Dashboard
• 4.2. U.S. Over-the-Counter (OTC) Glucose Biosensors Market: End Use Movement Analysis, USD Million, 2024 & 2030
• 4.3. Healthcare Professional Offices (HCPs)
  • 4.3.1. Healthcare Professional Offices (HCPs) Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
• 4.4. Specialty Clinics
  • 4.4.1. Specialty Clinics Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
• 4.5. Homecare
  • 4.5.1. Homecare Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 5. Competitive Landscape

• 5.1. Recent Developments & Impact Analysis by Key Market Participants
• 5.2. Company Categorization
• 5.3. Company Heat Map Analysis
• 5.4. Company Profiles
  • 5.4.1. DexCom, Inc.
    • 5.4.1.1. Participant's Overview
    • 5.4.1.2. Financial Performance
    • 5.4.1.3. Product Benchmarking
    • 5.4.1.4. Recent Developments/ Strategic Initiatives
  • 5.4.2. Abbott
    • 5.4.2.1. Participant's Overview
    • 5.4.2.2. Financial Performance
    • 5.4.2.3. Product Benchmarking
    • 5.4.2.4. Recent Developments/ Strategic Initiatives